Clinical Trials on Essential Hypertension in Australia

Total 400 results

ADARx Pharmaceuticals, Inc.
ADARx Australia Pty Ltd

Recruiting

Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension

Hypertension | Hypertension,Essential

Australia
Cibiem, Inc.

Unknown

First-In-Human Study Evaluating a Novel Catheter Device in Subjects With Treatment-Resistant Hypertension

Hypertension,Essential

Australia, Czechia, Germany
Curtin University

Active, not recruiting

Long-term Use of CCB and Breast Cancer Risk

Breast Cancer | Hypertension,Essential

Australia
Sankyo Pharma Gmbh

Completed

Olmesartan in Essential Hypertension

Essential Hypertension

Austria, Germany, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

Hypertension

Sweden, United States, Peru, Russian Federation, Romania, Mexico, Panama, Spain, Denmark, Italy, Greece, South Africa, Canada, Argentina, Australia, Colombia, Finland, Taiwan
Takeda

Completed

Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension

Essential Hypertension

Netherlands, Austria, Germany, Poland, United Kingdom
Sankyo Pharma Gmbh

Completed

Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension (OLMETREAT)

Essential Hypertension

France, Austria, Switzerland, Belgium, Germany, Italy, Netherlands, United Kingdom, Portugal
Daiichi Sankyo, Inc.

Completed

Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension

Essential Hypertension

France, Poland, Ukraine, Belgium, Germany, Spain, Bulgaria, Romania, Denmark, Russian Federation, Netherlands, Austria, Slovakia, Czechia
Imago BioSciences, Inc., a subsidiary of Merck...

Completed

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Myelofibrosis | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (PPV-MF) | Post-essential Thrombocythemia Myelofibrosis (PET-MF)

Germany, United States, Australia, Italy, United Kingdom
Gmax Biopharm Australia Pty Ltd.
Metaclinical; Syneos Heath

Completed

A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers

Pulmonary Arterial Hypertension

Australia
Royal Perth Hospital

Recruiting

Neuroinflammation in Hypertension Study (MINIHT)

Resistant Hypertension

Australia
University of Adelaide

Unknown

Effects of Renal Sympathetic Denervation on the Cardiac and Renal Functions in Patients With Drug-resistant Hypertension Through MRI Evaluation (RDN)

Uncontrolled Hypertension

Australia
Medical University of Vienna

Recruiting

Non-invasive Measurement of Retinal Blood Flow Based on Vessel Analysis and Fourier Domain Optical Coherence Tomography in Patients With Hypertensive Retinopathy

Hypertensive Retinopathy

Austria
Aerami Therapeutics

Completed

Safety, Tolerability, & Pharmacokinetics Study of Single & Multiple Inhaled Doses of Imatinib Inhalation Solution

Pulmonary Arterial Hypertension

Australia
Royal Victoria Eye and Ear Hospital
The Florey Institute of Neuroscience and Mental Health

Active, not recruiting

The Development of a System for Measurement of Tremor

Dystonia | Essential Tremor

Australia
Ji Xing Pharmaceuticals Australia Pty Ltd
Novotech (Australia) Pty Limited

Recruiting

JX09 SAD/MAD in Healthy Participants

Resistant Hypertension

Australia
United Therapeutics

Terminated

Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Australia
Sierra Oncology, Inc.

Completed

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, Canada, Australia
Merck Sharp & Dohme LLC

Recruiting

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Essential Thrombocythemia

Israel, Australia, Hong Kong, Japan, New Zealand, Taiwan, Korea, Republic of, United States, Spain
Cardiosonic

Unknown

Continued Safety and Performance of the TIVUS System

Hypertension, Resistant to Conventional Therapy

Australia
Novartis

Completed

Tolerability, Safety and Efficacy of SAD448 in Subjects With Ocular Hypertension

Ocular Hypertension

Australia
Sierra Oncology, Inc.

Completed

Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, Canada, Australia
Pharmosa Biopharm Inc.
Novotech (Australia) Pty Limited

Recruiting

Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults

Pulmonary Arterial Hypertension

Australia
Bayside Health

Unknown

Vasoactive Peptides in Portal Pressure

Portal Hypertension

Australia
Regina Steringer-Mascherbauer

Unknown

Imaging Control Study, 3D Echo, MR and RHC. (PARIS)

Pulmonary Arterial Hypertension WHO Group I

Austria
Theratocular Biotek Co.
Novotech (Australia) Pty Limited

Active, not recruiting

A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open Angle Glaucoma

Australia
Medtronic Vascular

Completed

Multi-electrode Radiofrequency Renal Denervation System Feasibility Study

Uncontrolled Hypertension

Australia, New Zealand
S*BIO

Completed

A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis

Myeloproliferative Disorders | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis

United States, Australia
Imago BioSciences, Inc., a subsidiary of Merck...

Completed

Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

Essential Thrombocythemia

United States, Australia, New Zealand, United Kingdom, Hong Kong, Germany, Italy
Regina Steringer-Mascherbauer

Unknown

3D Echo Evaluation of the Ventricles in Sclero Associated Severe PAH (EVA3D)

Pulmonary Arterial Hypertension

Austria
AOP Orphan Pharmaceuticals AG

Completed

Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia (ANAHYDRET)

Essential Thrombocythaemia

Austria, Czech Republic, France, Germany, Hungary, Italy, Lithuania, Poland, Singapore, Slovenia
Novartis Pharmaceuticals
Incyte Corporation

Terminated

A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis

Myelofibrosis

Spain, United Kingdom, Australia, Israel, Germany, Italy, Singapore, Austria, France
Bayside Health

Completed

Relationship of Vasoactive Peptide Levels to Portal Pressure and Patient Outcomes in Patients With Hepatic Cirrhosis

Portal Hypertension

Australia
Abbott Medical Devices

Completed

Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients (EnligHTN-I)

Hypertension

Australia, Greece
AOP Orphan Pharmaceuticals AG

Completed

Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia (ARETA)

Essential Thrombocythaemia

Poland, Slovakia, Bulgaria, Russian Federation, Romania, Croatia, Lithuania, Austria, Ukraine
Medical University of Graz
Ludwig Boltzmann Institute for Lung Vascular Research

Completed

Acute Effects of Benzbromaron on the Pulmonary Circulation

Idiopathic Pulmonary Arterial Hypertension

Austria
Syntara
Parexel

Recruiting

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Myelofibrosis

Taiwan, Australia, Korea, Republic of, United States
Respira Therapeutics, Inc.

Completed

A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Australia
Actelion

Completed

Pulmonary Artery Remodelling With Bosentan

Hypertension, Pulmonary

Australia
Erasmus Medical Center

Recruiting

Physiological-based Cord Clamping in Congenital Diaphragmatic Hernia (PinC)

Pulmonary Hypertension | Hernias, Diaphragmatic, Congenital | Hernia; Diaphragm Defect, Congenital

Belgium, Sweden, Austria, Australia, Germany, Netherlands, Italy
Baker Heart and Diabetes Institute

Completed

Sham Controlled Clinical Trial of Renal Denervation in Patients With Resistant Hypertension

Hypertension

Australia
Baker Heart and Diabetes Institute

Terminated

Renal Denervation for Resistant Hypertension (RDNP-2012-01)

Hypertension

Australia
Kona Medical Inc.

Completed

A Safety Evaluation of Renal Denervation Using Focused Therapeutic Ultrasound on Patients With Refractory Hypertension

Hypertension

Australia
VividWhite Pty Ltd

Recruiting

VividWhite Glaucoma Implant (VW-51) Pivotal Study

Glaucoma

Australia
Medical University of Graz

Completed

Estimation of Pulmonary Capillary Blood Volume in Pre- and Postcapillary Pulmonary Hypertension

Hypertension Pulmonary

Austria
Medical University of Graz

Enrolling by invitation

Identifying Markers of Disease Subtypes and Disease Progression in the Syndrome of Essential Tremor

Essential Tremor

Austria
Medical University of Graz
Ludwig Boltzmann Gesellschaft

Completed

Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography

Pulmonary Arterial Hypertension

Austria
Royal Perth Hospital
The University of Western Australia

Recruiting

Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension (OHT)

Hypertension | Obesity

Australia
Medical University of Graz
Ludwig Boltzmann Gesellschaft

Completed

Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography

Pulmonary Arterial Hypertension

Austria
Medical University of Graz

Withdrawn

Ambrisentan for Treatment of Portopulmonary Hypertension

Portopulmonary Hypertension

Austria

Clinical Trials on Essential Hypertension in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations